Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of a Group B Streptococcus Vaccine in Non Pregnant and Pregnant Women 18-40 Years of Age

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Group 1 (Non Pregnant Women): Healthy females 18-40 years of age inclusive.~* Group 2 (Healthy Pregnant Women): Healthy pregnant women 18-40 yrs of age (between 28-35 weeks gestation)~Exclusion Criteria:~* Group 1 (Non Pregnant Women): Pregnant or nursing; History of severe allergy to previous vaccines; Known HIV positive~* Group 2 (Healthy Pregnant Women): History of severe allergy to previous vaccines; Known HIV positive

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- 1: GBS Trivalent Vaccine with aluminium - 20/20/20 μg (Type: EXPERIMENTAL): Non-pregnant women who received two injections of 20/20/20 μg dose of Group B Streptococcus (GBS) Trivalent Vaccine with aluminum.
- 2: Placebo - Sterile saline (Type: PLACEBO_COMPARATOR): Non-Pregnant Women who received two injection of saline solution.
- 3: GBS Trivalent Vaccine - 0.5/0.5/0.5 µg (Type: EXPERIMENTAL): Pregnant women who received one injection of 0.5/0.5/0.5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.
- 4: GBS Trivalent Vaccine - 2.5/2.5/2.5 µg (Type: EXPERIMENTAL): Pregnant Women who received one injection of 2.5/2.5/2.5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.
- 5: GBS Trivalent Vaccine - 5/5/5 µg (Type: EXPERIMENTAL): Pregnant women who received one injection of 5/5/5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.
- 6: Placebo - Sterile saline (Type: PLACEBO_COMPARATOR): Pregnant Women who received one injection of saline solution.

Based on this trial design, predict the completion outcome and termination type (if applicable).